Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study
- 1 June 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (11), 3477-3486
- https://doi.org/10.1158/1078-0432.ccr-07-4521
Abstract
Purpose: To determine the toxicity, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of oral gemcitabine (2′,2′-difluorodeoxycytidine; dFdC) in patients with cancer.Keywords
This publication has 26 references indexed in Scilit:
- Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion‐exchange liquid chromatography coupled with tandem mass spectrometryJournal of Mass Spectrometry, 2006
- Characterization of Lipophilic Gemcitabine Prodrug−Liposomal Membrane Interaction by Differential Scanning CalorimetryMolecular Pharmaceutics, 2006
- Squalenoyl Nanomedicines as Potential TherapeuticsNano Letters, 2006
- Gemcitabine Pharmacogenomics: Cytidine Deaminase and Deoxycytidylate Deaminase Gene Resequencing and Functional GenomicsClinical Cancer Research, 2006
- Phase I clinical trial of fixed–dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulationCancer, 2004
- Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) StudyGynecologic Oncology, 2004
- Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- GemcitabineDrugs, 1997
- In vitro antiproliferative and metabolic activity of eight novel 5-fluorinated uracil nucleosidesEuropean Journal of Cancer and Clinical Oncology, 1991